GlassScriptPhysician profile
Aslam Godil
NPI 1093720682
$1,402.84
in general payments reported to CMS, 2019-2025
20 companies · $95.78 in 2025
The $95.78 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.02 · 2021: $102 · 2022: $43.96 · 2023: $360 · 2024: $710 · 2025: $95.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $489.01 | 2021-2025 | |
| Gilead Sciences, INC. | $158.35 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.90 | 2023-2025 | Entyvio |
| Janssen Biotech, INC. | $127.89 | 2023-2024 | Stelara, Tremfya |
| Mallinckrodt Hospital Products INC. | $100.13 | 2024 | Terlivaz |
| Pfizer INC. | $64.30 | 2024 | |
| Celgene Corporation | $50.24 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $43.50 | 2024 | Dupixent |
| Madrigal Pharmaceuticals | $32.63 | 2024 | Resmetirom |
| Janssen Pharmaceuticals, INC | $26.42 | 2025 | Tremfya |
| Genzyme Corporation | $22.39 | 2024 | |
| Vivus LLC | $21.48 | 2024 | Pancreaze |
| Aimmune Therapeutics, INC. | $18.19 | 2024 | |
| Lilly USA, LLC | $18.15 | 2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $16.76 | 2025 | Iqirvo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $15.66 | 2019 | |
| Qol Medical, LLC | $15.47 | 2019 | |
| Braintree Laboratories, INC. | $15.27 | 2023 | Suflave |
| Phathom Pharmaceuticals, INC. | $12.81 | 2023 | Voquezna |
| Olympus America INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aslam Godil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.